JP2022501423A5 - - Google Patents
Info
- Publication number
- JP2022501423A5 JP2022501423A5 JP2021538933A JP2021538933A JP2022501423A5 JP 2022501423 A5 JP2022501423 A5 JP 2022501423A5 JP 2021538933 A JP2021538933 A JP 2021538933A JP 2021538933 A JP2021538933 A JP 2021538933A JP 2022501423 A5 JP2022501423 A5 JP 2022501423A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical
- vesicle
- cholesterol
- formulation
- pharmaceutical agent
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1814959.1A GB201814959D0 (en) | 2018-09-14 | 2018-09-14 | Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses |
| GB1814959.1 | 2018-09-14 | ||
| PCT/GB2019/000134 WO2020053541A1 (en) | 2018-09-14 | 2019-09-13 | Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501423A JP2022501423A (ja) | 2022-01-06 |
| JP2022501423A5 true JP2022501423A5 (https=) | 2022-09-21 |
| JPWO2020053541A5 JPWO2020053541A5 (https=) | 2022-09-21 |
| JP7487892B2 JP7487892B2 (ja) | 2024-05-21 |
Family
ID=64013381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021538933A Active JP7487892B2 (ja) | 2018-09-14 | 2019-09-13 | 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11524080B2 (https=) |
| EP (1) | EP3849511B1 (https=) |
| JP (1) | JP7487892B2 (https=) |
| AU (1) | AU2019337456B9 (https=) |
| CA (1) | CA3113047A1 (https=) |
| DK (1) | DK3849511T3 (https=) |
| GB (2) | GB201814959D0 (https=) |
| WO (1) | WO2020053541A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4125845A4 (en) * | 2020-04-02 | 2024-05-15 | Southern Research Institute | NEW 2-PYRIMIDONE ANALOGUES AS EFFECTIVE ANTIVIRAL AGENTS AGAINST ALPHAVIRES |
| CN116350588B (zh) * | 2023-01-13 | 2024-09-24 | 华中科技大学 | 一种载抗生素微生物囊泡及其制备方法和应用 |
| GB202303291D0 (en) * | 2023-03-07 | 2023-04-19 | Secr Defence | Medicament and medicament combination for use in the treatment of infectious disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323561A (en) * | 1977-09-06 | 1982-04-06 | Temple University Of The Commonwealth System Of Higher Education | Process of enhancing immmunogenic response in mammals by the administration of synthetic glycolipid adjuvants |
| JPH04159216A (ja) * | 1990-10-22 | 1992-06-02 | Japan Tobacco Inc | グルコサミン誘導体を膜材として含有するリポソーム |
| GB9515868D0 (en) | 1995-08-02 | 1995-10-04 | Proteus Molecular Design | Therapeutic method |
| US7648982B2 (en) * | 2003-02-28 | 2010-01-19 | Ym Biosciences Inc. | Opioid delivery system |
| CA2721870C (en) * | 2008-04-21 | 2020-12-22 | Tissue Regeneration Therapeutics, Inc. | Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents |
| AU2010270722B2 (en) * | 2009-07-06 | 2015-06-04 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| US9907746B2 (en) * | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| GB0916630D0 (en) | 2009-09-22 | 2009-11-04 | Secr Defence | Antibody |
| MX342138B (es) * | 2010-07-06 | 2016-09-14 | Variation Biotechnologies Inc | Composiciones y metodos para el tratamiento de influenza. |
| WO2013059617A1 (en) * | 2011-10-21 | 2013-04-25 | Ndsu Research Foundation | Liposome compositions and methods of use |
| US20140328876A1 (en) * | 2011-11-18 | 2014-11-06 | Variation Biotechnologies Inc. | Synthetic derivatives of mpl and uses thereof |
| US20140356399A1 (en) * | 2012-01-12 | 2014-12-04 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
| US20150079077A1 (en) * | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
| US9969794B2 (en) * | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| US9539273B2 (en) * | 2012-08-04 | 2017-01-10 | Edh Biotech Corp | Targeted delivery of anti-fungal agents |
| US9987227B2 (en) * | 2013-10-22 | 2018-06-05 | Aradigm Corporation | Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile |
| US9968555B2 (en) | 2014-04-08 | 2018-05-15 | Aradigm Corporation | Liposomal formulations that form drug nanocrystals after freeze-thaw |
| MX386433B (es) * | 2014-08-14 | 2025-03-18 | L E A F Holdings Group Llc | Fármaco de afinidad encapsulado en liposoma. |
-
2018
- 2018-09-14 GB GBGB1814959.1A patent/GB201814959D0/en not_active Ceased
-
2019
- 2019-09-12 GB GB1913128.3A patent/GB2578678B/en active Active
- 2019-09-13 DK DK19778580.1T patent/DK3849511T3/da active
- 2019-09-13 WO PCT/GB2019/000134 patent/WO2020053541A1/en not_active Ceased
- 2019-09-13 CA CA3113047A patent/CA3113047A1/en active Pending
- 2019-09-13 US US17/273,059 patent/US11524080B2/en active Active
- 2019-09-13 JP JP2021538933A patent/JP7487892B2/ja active Active
- 2019-09-13 EP EP19778580.1A patent/EP3849511B1/en active Active
- 2019-09-13 AU AU2019337456A patent/AU2019337456B9/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025015674A (ja) | 光免疫療法のための組成物、組み合わせおよび関連方法 | |
| US20170165375A1 (en) | Antibiotic protocells and related pharmaceutical formulations and methods of treatment | |
| JP6050822B2 (ja) | ナノ粒子、ナノ粒子の調製のための処理、および癌治療および食品関連化合物を含む医療分野における両親媒性分子または疎水性分子ための担体としてのナノ粒子の使用 | |
| US20250255978A1 (en) | Drug-delivery nanoparticles and treatments for drug-resistant cancer | |
| JP2022501423A5 (https=) | ||
| BG108274A (bg) | Конюга'и о' хидрок'иалкил'корбяла (has) и ак'ив...н ингр...ди...н' | |
| CN106604750A (zh) | 治疗骨髓瘤 | |
| EA032475B1 (ru) | Фармацевтическая композиция для снижения продолжительности и/или тяжести диареи, заболеваемости и/или смертности пациента, инфицированного clostridium diffcile или имеющего риск указанного заражения, и ее применение | |
| CA2942234A1 (en) | Liposomal compositions for mucosal delivery | |
| CN105163743A (zh) | 用于治疗幽门螺杆菌的药物组合物 | |
| CN110573166A (zh) | 用于癌症治疗的吉西他滨衍生物 | |
| JP4513007B2 (ja) | 薬物吸収性改善剤 | |
| AU779922B2 (en) | Formulations for parenteral use of estramustine phosphate and amino acids | |
| JP7487892B2 (ja) | 医薬ベシクル製剤を調製するための方法、ならびに関連する製品および使用 | |
| JPWO2020053541A5 (https=) | ||
| JP2026001029A (ja) | がん治療のための化学療法剤とα－ラクトアルブミン－オレイン酸複合体の組合せ | |
| WO2017097783A1 (en) | Novel adjuvant formulations | |
| JPH0136445B2 (https=) | ||
| JP2022529996A (ja) | 高濃度タンパク質製剤の粘度を低減させるための低分子量ポリビニルピロリドン（ｐｖｐ）の使用 | |
| CN111315399B (zh) | 用于药物递送的葡萄糖敏感性组合物 | |
| CN120826242A (zh) | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 | |
| CN110787301A (zh) | CTLA-4 Aptamer靶向共负载PD-1 siRNA纳米颗粒及其制备和应用 | |
| JP7149991B2 (ja) | 発泡剤を含む抗微生物組成物 | |
| CN105263499B (zh) | 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合 | |
| CN115721732A (zh) | 抗体偶联药物的药物组合物、制剂及其制备方法、用途 |